A regulatory requirement non-interventional study to monitor the safety and effectiveness of Jardiance® (empagliflozin, 10mg) in Korean patients with chronic heart failure (NYHA class II-IV)

09/12/2021
02/07/2025
EU PAS number:
EUPAS44641
Study
Ongoing
Subscribe
Download as PDF
Study identification

EU PAS number

EUPAS44641

Study ID

47613

Official title and acronym

A regulatory requirement non-interventional study to monitor the safety and effectiveness of Jardiance® (empagliflozin, 10mg) in Korean patients with chronic heart failure (NYHA class II-IV)

DARWIN EU® study

No

Study countries

Korea, Republic of

Study description

To monitor the safety profile and effectiveness of JARDIANCE® in Korean patients with chronic heart failure (NYHA class II-IV)

Study status

Ongoing
Research institutions and networks

Institutions

Contact details

Hyerim Hwang

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:

Date of interim report, if expected

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only